Therefore, if in vivo SorCS1 overexpression rescues AD pathology and cognitive deficits, it will be important to dissect which SorCS1 targets are involved in each in vivo rescue effect, and identifying these could provide multiple avenues to investigate the development of novel therapeutic strategies for AD. This evidence concerns the gene SORCS1 and Alzheimer disease.